<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031624</url>
  </required_header>
  <id_info>
    <org_study_id>CDX0159-05</org_study_id>
    <nct_id>NCT05031624</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of Single Ascending Doses of Subcutaneous CDX-0159 to Assess the Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the safety and pharmacokinetics of CDX-0159 administered&#xD;
      subcutaneously in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CDX-0159 is a humanized monoclonal antibody that binds to a protein called KIT that is&#xD;
      expressed on mast cells.&#xD;
&#xD;
      The study will evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX-0159&#xD;
      administered subcutaneously in healthy subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Safety of single, ascending doses of CDX-0159 as determined by percentage of participants with adverse events as assessed by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Trials</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CDX-0159 serum evaluations over time</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>CDX-0159 serum concentrations will be measured at specified visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum tryptase levels over time</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>The effect of CDX-0159 on serum tryptase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels over time</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>The effect of CDX-0159 on stem cell factor levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Anti-drug Antibody development over time</measure>
    <time_frame>Day 1 to Day 85</time_frame>
    <description>Patients will be monitored for the development of anti-drug antibodies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>CDX-0159</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of CDX-0159</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive a single dose of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-0159</intervention_name>
    <description>Single subcutaneous dose of one of four dosages of CDX-0159</description>
    <arm_group_label>CDX-0159</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Single subcutaneous dose of normal saline</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  An informed consent signed and dated by the subject.&#xD;
&#xD;
          -  Healthy volunteer aged 18-55.&#xD;
&#xD;
          -  In generally good health and without significant medical conditions based on physical&#xD;
             exam, ECG, and laboratory test results.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.5 kg/m2 to ≤ 35 kg/m2&#xD;
&#xD;
          -  No medication other than mild analgesics, vitamins and mineral supplements or, oral&#xD;
             contraceptives.&#xD;
&#xD;
          -  Both males and females of child bearing potential must agree to use a medically&#xD;
             accepted contraceptive regimen during study and up to 150 days afterwards.&#xD;
&#xD;
          -  Not a current smoker, vaper, or regular user of any nicotine or cannabinoid containing&#xD;
             products&#xD;
&#xD;
          -  Willing to follow all study rules&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  History of anaphylaxis or systemic reactions to food or other triggers&#xD;
&#xD;
          -  Autoimmune disorders requiring more than topical medication&#xD;
&#xD;
          -  Vaccination with live vaccines within 4 months prior to screening visit (subjects must&#xD;
             agree to avoid live vaccination during the study and 4 months after).&#xD;
&#xD;
          -  Positive urine test for alcohol and drugs of abuse.&#xD;
&#xD;
        Other Protocol defined inclusion and exclusion criteria could apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <phone>844-723-9363</phone>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion, Inc</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Badgett</last_name>
      <email>angie.badgett@celerion.com</email>
    </contact>
    <investigator>
      <last_name>Allen Hunt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CDX0159-05</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

